ArticleNeurotrauma reports2025
Long-Term Functional Recovery after Severe Traumatic Brain Injury with Type II Diffuse Injury.
Article in Neurotrauma reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to describe the late clinical outcomes of patients with severe traumatic brain injury (sTBI) and the risk factors associated with it. Patients were enrolled between April 2012 and January 2015 and followed until January 2022. The inclusion criteria were age 16-65 years, Glasgow Coma Scale ≤8 on admission, diagnosis of blunt TBI with Marshall diffuse injury type II on initial computerized tomography (CT), and alive at discharge. Clinical, laboratory, and radiological data from admission were collected. Glasgow Outcome Scale Extended (GOSE), Functional Independence Measure, and Zarit Burden Interview (ZBI) were assessed in the follow-up. Sixty-five patients were included, with a median follow-up time of 8 years. Nineteen (29.2%) patients had good recovery (GOSE 7-8), and 10 (15.3%) had moderate-to-severe sequelae (GOSE 4-6). Thirty-six (55.4%) patients died after discharge, and most of them in the first 3 months after discharge (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.